CN107551318A - Contain the polylactide tunica fibrosa and preparation method of poly- (L lysines) the VAPG/ nucleic acid complexes of glucan g - Google Patents
Contain the polylactide tunica fibrosa and preparation method of poly- (L lysines) the VAPG/ nucleic acid complexes of glucan g Download PDFInfo
- Publication number
- CN107551318A CN107551318A CN201710554356.3A CN201710554356A CN107551318A CN 107551318 A CN107551318 A CN 107551318A CN 201710554356 A CN201710554356 A CN 201710554356A CN 107551318 A CN107551318 A CN 107551318A
- Authority
- CN
- China
- Prior art keywords
- poly
- nucleic acid
- vapg
- glucan
- lysine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Artificial Filaments (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to the polylactide tunica fibrosa and preparation method that one kind contains poly- (L lysines) the VAPG/ nucleic acid complexes of glucan g.Tunica fibrosa by 600~1200nm of diameter 50~100nm of fiber and diameter glucan g it is poly- (LLysine) VAPG/ nucleic acid complexes nano-particle composition, fiber film thickness is 60~150 μm.By by glucan g it is poly- (LLysine) VAPG polymer contains the complex solution of nucleic acid as aqueous phase; using PELCL or PLGA solution as oil phase; the electrospun fiber membrane for containing nucleic acid complexes is prepared using emulsion electrospinning mode; the perfect cladding to nucleic acid is realized, protects its bioactivity, it is slow down and prominent releases; it is prominent to release rate below 20%; so that nucleic acid continues controlled release into vascular smooth muscle cells, there is good biocompatibility and biodegradability, for organizational project and field of gene.
Description
Technical field
The present invention relates to one kind contain glucan-g- it is poly- (L- lysine)-VAPG/ nucleic acid complexes polylactide copolymerization
Fibres film and preparation method, belong to organizational project and field of gene.
Background technology
Electrospun fiber membrane has higher specific surface area and porosity, the electricity that can be prepared by adjusting electrospinning parameters
Spinning fiber film preferably analog cell epimatrix environment (ECM), is advantageous to the adhesion, growth and nutrition transmission of cell, is organizing
Engineering rack field has broad application prospects (Rayatpisheh S, Heath DE, Shakouri A, Rujitanaroj
PO,Chew SY,Chan-Park MB.Combining cell sheet technology and electrospun
scaffolding for engineered tubular,aligned,and contractile blood
vessels.Biomaterials,2014,35:2713-9).Polyethylene glycol (lactide-co-caprolactone) and poly- (second friendship
Ester-co- lactides) it is that there is good biocompatibility and the electrospinning material of biodegradability, the modification of ethylene glycol improves
The hydrophily of PLA, and the proportion adjustment of glycolide and lactide can optimize degradation time, mechanical property
It is excellent, tunica fibrosa is prepared into by electrostatic spinning, can as organizational project timbering material (Zhao W, Li J, Jin K,
Liu W,Qiu X,Li C.Fabrication of functional PLGA-based electrospun scaffolds
and their applications in biomedical engineering.Mater.Sci.Eng.,C,2016,59:
1181-94)。
Important regulating and controlling person of the small molecule RNA (miRNA) as gene expression, also plays in angiocardiopathy field
Positive effect.It is reported that miR-145 can improve gene downstream and promote blood by suppressing the expression of KLF4/5 target genes
Pipe SMC differentiation factor myocardin expression, and shrinkage type smooth muscle cell marker gene SM- α-actin,
SM-22 α and SM-MHC up-regulated expression, the phenotype, propagation and migration of vascular smooth muscle cells are adjusted, prevents reconstructing blood vessel mistake
Endometrial hyperplasia and ISR in journey.Therefore, miR-145 is introduced in tissue engineering bracket material and is advantageous to long period regulation osculum
Patency (Cordes KR, Sheehy NT, White MP, Berry EC, Morton SU, the Muth AN, Lee of footpath blood vessel
AN,Miano JM,Srivastava D.miR-145and miR-143regulate smooth muscle cell fate
and plasticity.Nature,2009,460:705-10).The nucleic acid such as miRNA are vulnerable to the degraded of nuclease, exposed
Cycle period is short in vivo by miRNA, and non-specific intake easily causes bio-toxicity, in consideration of it, this seminar have developed one
Nucleic acid carrier glucan-the g- of low toxicity and high transfection kind with targeting smooth muscle cell it is poly- (L- lysine)-VAPG, structural formula
It is as follows：
In formula, k=18~24, r=13~19, n=1~8, l=7~22, the advantage of the carrier be by polysaccharide with it is more
Peptide combines, and good biocompatibility, toxicity is low, and due to Smooth Muscle Cells Adhesion peptide VAPG presence, can guide nucleic acid medicine
Thing targeting enters smooth muscle cell, improves transfection efficiency, reduces the side effect contacted with non-specific cell, especially blood
Endothelial cell.However, the miRNA compounds injection that carrier is contained enters in vivo, it is impossible to efficiently controls miRNA administration
Amount, easily cause the wound of the excessive caused biological side effect of single administration or Repeated Operation administration.Moreover, miRNA can not be accurate
Really reaching lesion site can also organize to produce toxic action to others.Existing document report, the miR-145 that ssPEI is contained
It is used for the propagation and phenotype (Che HL, Bae of modulating vascular smooth muscle cell on FirebirdTM coated in hyaluronic acid parcel
IH,Lim KS,Uthaman S.,Song IT,Lee H,Lee D,Kim WJ,Ahn Y,Park IK,Jeong MH.Novel
fabrication of microrna nanoparticle-coated coronary stent for prevention of
post-angioplasty restenosis.Korean Circulation Journal,2016,46(1):23-32).So
And the load of miR-145 compounds is entered in electrospun fiber membrane and extends its cycle period and continues slowly to discharge, and then long-term tune
The propagation and phenotype of vascular smooth muscle cells are saved, prevents endometrial hyperplasia and ISR during reconstructing blood vessel, at present document
In have no report.
The content of the invention
It is an object of the invention to provide one kind contain glucan-g- it is poly- (L- lysine)-VAPG/ nucleic acid complexes it is poly-
Lactide copolymer tunica fibrosa and preparation method.Based on emulsion electrostatic spinning technology, glucan-g- polylysines-VAPG is utilized
For genophore, protect the activity of nucleic acid, realize that nucleic acid is discharged into vascular smooth muscle cells step by step by tunica fibrosa, make its
Effective activity is kept in longer time, adjusts the biological activity of smooth muscle cell.Without frequent drug administration, avoid simultaneously
The generation of medicine " prominent to release " phenomenon.
To reach above-mentioned purpose, the present invention is realized by the following technical programs：
One kind contain glucan-g- it is poly- (L- lysine)-VAPG/ nucleic acid complexes polylactide co polymer tunica fibrosa,
Tunica fibrosa be by a diameter of 600~1200nm electrospinning fibre and a diameter of 50~100nm glucan-g- it is poly- (L- rely ammonia
Acid)-VAPG/ nucleic acid complexes nanoparticles are molecular, and the thickness of tunica fibrosa is 60~150 μm.In every milligram of electrospun fiber membrane
Nucleic acid containing 50~200 nanograms.
Glucan-the g- it is poly- (L- lysine)-VAPG, structural formula is as follows：
K=18~24, r=13~19, n=1~8, l=7~22.
Described nucleic acid is miRNA, described polylactide co polymer include polyethylene glycol-b- it is poly- (lactide-co- oneself
Lactone) (PELCL) or poly- (lactide-co-glycolide) (PLGA), the wherein mol ratio of lactide and caprolactone is 3:1.
The present invention contain glucan-g- it is poly- (L- lysine)-VAPG/ nucleic acid complexes polylactide co polymer fiber
The preparation method of film, comprises the following steps：
(1) PELCL or PLGA are dissolved in chloroform/N, N '-dimethyl formamide in the mixed solvent, add 10~12mg/mL
F127 as emulsifying agent, be configured to solution that concentration is 100~300mg/mL as oil phase；
(2) at room temperature, by glucan-g- it is poly- (L- lysine)-VAPG polymer and nucleic acid is dissolved in coke acid two respectively
In ethyl ester (DEPC) water, and according to glucan-g- it is poly- (L- lysine)-VAPG polymer and miRNA mass ratioes be (2~4)：1
Compound 15~45min at room temperature, the TE buffer solutions for adding 52~292 μ L form homogeneous aqueous phase solution；
(3) according to the volume ratio 1 of aqueous phase/oil phase:10~1:25, aqueous phase solution is added in oil phase, vortex oscillation 0.5
~2 hours obtained dispersion liquids, using single syringe pump apparatus, carry out electrospinning, obtain thickness be 60~150 μm contain glucan-
G- it is poly- (L- lysine)-VAPG/ nucleic acid complexes polylactide co polymer tunica fibrosa.
The weight average molecular weight of the PELCL is (5~10) × 104, PLGA weight average molecular weight is (5~10) × 104, Portugal
Glycan-g- it is poly- (L- lysine)-VAPG weight average molecular weight is (1.5~3.6) × 104。
Using single syringe pump apparatus, using voltage as 10~16kV, it is 12~16cm to receive distance, and it is 0.3 to disperse flow quantity
~0.6mL/h carries out electrospinning.
The chloroform/N,N-dimethylformamide mixed solvent volume ratio 8:1~4:1.
It is an advantage of the current invention that by by glucan-g- it is poly- (L- lysine)-VAPG polymer contains the compound of nucleic acid
Thing solution, using PELCL or PLGA solution as oil phase, is prepared by the way of emulsion electrospinning as aqueous phase and contains nucleic acid complexes
Electrospun fiber membrane, realize the perfect cladding to nucleic acid, protect its bioactivity, slow down its it is prominent release, it is prominent to release rate and exist
Less than 20%, and cause nucleic acid to continue controlled release into vascular smooth muscle cells, adjust its phenotype and propagation activity.This
Invention preparation process is simple and easy, and obtained tunica fibrosa has good biocompatibility and biodegradability, available for group
Weaver's journey and field of gene.
Brief description of the drawings
Fig. 1 be embodiment 1 obtained by load glucan-g- it is poly- (L- lysine)-VAPG/ nucleic acid complexes PLGA it is fine
Tie up film electron scanning micrograph；
Fig. 2 be embodiment 1 obtained by load glucan-g- it is poly- (L- lysine)-VAPG/ nucleic acid complexes PLGA it is fine
Tie up film laser co-focusing photo.
Fig. 3 be embodiment 1 obtained by load glucan-g- it is poly- (L- lysine)-VAPG/ nucleic acid complexes PLGA it is fine
Tie up film release profiles.
Embodiment
Technical scheme is further explained below by case study on implementation, following case study on implementation is to the present invention
Further explanation, be not intended to limit the present invention the scope of application.
Embodiment 1
(1) weight average molecular weight is weighed as 1 × 105PLGA (lactides：Glycolide=3:1) 400mg is dissolved in 4mL volume ratios
For 4:1 chloroform and N, the in the mixed solvent of N '-dimethyl formamide, while 48mg F127 is added as emulsifying agent, room temperature
It is stirred overnight and obtains uniform oil-phase solution (O).
(2) weight average molecular weight is weighed as 3.6 × 104Glucan-g- it is poly- (L- lysine)-VAPG polymer 10mg, be dissolved in
In 2mL DEPC water；The DEPC water compound concentration that 25 μ L are added in 1OD miRNA is 1.32mg/mL miRNA solution；Press
It is 2 according to polymer/miRNA:1 mass ratio, take 60 μ L miRNA solution and 32 μ L polymer solution room temperature compound 15~
45min simultaneously adds 68 μ L TE buffer solutions and forms homogeneous aqueous phase solution (W).
(3) according to water-oil factor 1:25,4mL oil-phase solution and above-mentioned 160 μ L aqueous phase solution are stirred 0.5~2h
Form W/O dispersion liquids.Dispersion liquid is advanced into 5mL syringe, using single syringe pump electric spinning equipment, using voltage as 16kV,
Scattered flow quantity be 0.6mL/h, receives distance and carries out electrospinning for 12cm, be collected into after 10h fibre diameter be 900nm~
1200nm, thickness are 100~150 μm of tunica fibrosa.Fig. 1 is that the PLGA tunica fibrosas of obtained load miRNA compounds scan
Electron micrograph, Fig. 2 are the PLGA tunica fibrosa laser co-focusing photos of obtained load miRNA compounds.Fig. 3 is institute
The PLGA tunica fibrosa release profiles of obtained load miRNA compounds.It can be seen that in this sample miRNA theory
The amount of containing is 200ng/mg (miRNA/PLGA), and actually the amount of containing reaches 165ng/mg (miRNA/PLGA), and envelop rate reaches
More than 80%, prominent to release rate below 20%, total burst size in two months reaches 90%, can reach the effect of sustained release administration
Fruit.
Embodiment 2
(1) weight average molecular weight is weighed as 7.5 × 104PLGA (lactides：Glycolide=3:1) 800mg is dissolved in 4mL volumes
Than for 6:1 chloroform and N, N ' dimethylformamide in the mixed solvent, while add 44mg F127 as emulsifying agent, room temperature
It is stirred overnight and obtains uniform oil-phase solution (O).
(2) weight average molecular weight is weighed as 2.1 × 104Glucan-g- it is poly- (L- lysine)-VAPG polymer 10mg, be dissolved in
In 2mL DEPC water；The DEPC water compound concentration that 25 μ L are added in 1OD miRNA is 1.32mg/mL miRNA solution, and
It is 3 according to polymer/miRNA:1 mass ratio, take 60 μ L miRNA solution and 48 μ L polymer solution room temperature compound 15~
45min simultaneously adds 52 μ L TE buffer solutions and forms uniform aqueous phase solution (W).
(3) according to water-oil factor 1:25,4mL oil-phase solution and above-mentioned 160 μ L aqueous phase solution are stirred 0.5~2h
Form W/O dispersion liquids.Above-mentioned dispersion liquid is advanced into 5mL syringe, using single syringe pump electric spinning equipment, using voltage as
13kV, it is 0.4mL/h to disperse flow quantity, receives distance and carries out electrospinning for 14cm, being collected into fibre diameter after 10h is
700nm~1000nm, thickness are 100~150 μm of tunica fibrosa.The miRNA theory amount of containing is 100ng/mg in this sample
(miRNA/PLGA), actually the amount of containing reaches 76ng/mg (miRNA/PLGA), and envelop rate reaches more than 70%, prominent to release rate and exist
Less than 20%.
Embodiment 3
(1) weight average molecular weight is weighed as 5 × 104PLGA (lactides：Glycolide=3:1) 1200mg is dissolved in 4mL volumes
Than for 8:1 chloroform and N, N ' dimethylformamide in the mixed solvent, while add 40mg F127 as emulsifying agent, room temperature
It is stirred overnight and obtains uniform oil-phase solution (O).
(2) weight average molecular weight is weighed as 1.5 × 104Glucan-g- it is poly- (L- lysine)-VAPG polymer 10mg, be dissolved in
In 2mL DEPC water；The DEPC water compound concentration that 25 μ L are added in 1OD miRNA is 1.32mg/mL miRNA solution, and
It is 4 according to polymer/miRNA:1 mass ratio, take 45 μ L miRNA solution and 48 μ L polymer solution room temperature compound 15~
45min simultaneously adds 107 μ L TE buffer solutions and forms uniform aqueous phase solution (W).
(3) according to water-oil factor 1:20,4mL oil-phase solution and above-mentioned 200 μ L aqueous phase solution are stirred 0.5~2h
Form W/O dispersion liquids.Above-mentioned dispersion liquid is advanced into 5mL syringe, using single syringe pump electric spinning equipment, using voltage as
10kV, it is 0.3mL/h to disperse flow quantity, receives distance and carries out electrospinning for 16cm, being collected into fibre diameter after 10h is
800nm~1000nm, thickness are 100~150 μm of tunica fibrosa.The miRNA theory amount of containing is 50ng/mg in this sample
(miRNA/PLGA), actually the amount of containing reaches 35ng/mg (miRNA/PLGA), and envelop rate reaches 70%, it is prominent release rate 20% with
Under.
Embodiment 4
(1) weight average molecular weight is weighed as 1 × 105PELCL 400mg be dissolved in 4mL volume ratios for 4:1 chloroform and N, N '
The in the mixed solvent of dimethylformamide, while the F127 for adding 48mg is stirred overnight at room temperature acquisition uniformly as emulsifying agent
Oil-phase solution (O).
(2) weight average molecular weight is weighed as 3.6 × 104Glucan-g- it is poly- (L- lysine)-VAPG polymer 10mg, be dissolved in
In 2mL DEPC water；The DEPC water compound concentration that 25 μ L are added in 1OD miRNA is 1.32mg/mL miRNA solution, and
It is 2 according to polymer/miRNA:1 mass ratio, take 60 μ L miRNA solution and 32 μ L polymer solution room temperature compound 15~
45min simultaneously adds 158 μ L TE buffer solutions and forms uniform aqueous phase solution (W).
(3) according to water-oil factor 1:16,4mL oil-phase solution and above-mentioned 250 μ L aqueous phase solution are stirred 0.5~2h
Form W/O dispersion liquids.Above-mentioned dispersion liquid is advanced into 5mL syringe, using single syringe pump electric spinning equipment, using voltage as
13kV, it is 0.4mL/h to disperse flow quantity, receives distance and carries out electrospinning for 14cm, being collected into fibre diameter after 10h is
900nm~1100nm, thickness are 100~150 μm of tunica fibrosa.The miRNA theory amount of containing is 200ng/mg in this sample
(miRNA/PELCL), actually the amount of containing reaches 150ng/mg (miRNA/PELCL), and envelop rate reaches 75%, prominent to release rate 20%
Below.
Embodiment 5
(1) weight average molecular weight is weighed as 6.5 × 104PELCL 800mg be dissolved in 4mL volume ratios for 6:1 chloroform and N,
The in the mixed solvent of N ' dimethylformamides, while the F127 for adding 44mg is stirred overnight at room temperature acquisition uniformly as emulsifying agent
Oil-phase solution (O).
(2) weight average molecular weight is weighed as 2.1 × 104Glucan-g- it is poly- (L- lysine)-VAPG polymer 10mg, be dissolved in
In 2mL DEPC water；The DEPC water compound concentration that 25 μ L are added in 1OD miRNA is 1.32mg/mL miRNA solution, and
It is 3 according to polymer/miRNA:1 mass ratio, take 45 μ L miRNA solution and 48 μ L polymer solution room temperature compound 15~
45min, and the TE buffer solutions for adding 292 μ L form uniform aqueous phase solution (W).
(3) according to water-oil factor 1:10,4mL oil-phase solution and above-mentioned 400 μ L aqueous phase solution are stirred 0.5~2h
Form W/O dispersion liquids.Above-mentioned dispersion liquid is advanced into 5mL syringe, using single syringe pump electric spinning equipment, using voltage as
16kV, it is 0.6mL/h to disperse flow quantity, receives distance and carries out electrospinning for 12cm, being collected into fibre diameter after 10h is
800nm~1000nm, thickness are 100~150 μm of tunica fibrosa.The miRNA theory amount of containing is 100ng/mg in this sample
(miRNA/PELCL), actually the amount of containing reaches 70ng/mg (miRNA/PELCL), and envelop rate reaches 70%, prominent to release rate 20%
Below.
Embodiment 6
(1) weight average molecular weight is weighed as 5 × 104PELCL 1200mg be dissolved in 4mL volume ratios for 8:1 chloroform and N, N '
The in the mixed solvent of dimethylformamide, while the F127 for adding 40mg is stirred overnight at room temperature acquisition uniformly as emulsifying agent
Oil-phase solution (O).
(2) weight average molecular weight is weighed as 1.5 × 104Glucan-g- it is poly- (L- lysine)-VAPG polymer 10mg, be dissolved in
In 2mL DEPC water；The DEPC water compound concentration that 25 μ L are added in 1OD miRNA is 1.32mg/mL miRNA solution, and
It is 4 according to polymer/miRNA:1 mass ratio, take 45 μ L miRNA solution and 48 μ L polymer solution room temperature compound 15~
45min simultaneously adds 107 μ L TE buffer solutions and forms uniform aqueous phase solution (W).
(3) according to water-oil factor 1:20,4mL oil-phase solution and above-mentioned 200 μ L aqueous phase solution are stirred 0.5~2h
Form W/O dispersion liquids.Above-mentioned dispersion liquid is advanced into 5mL syringe, using single syringe pump electric spinning equipment, using voltage as
10kV, it is 0.3mL/h to disperse flow quantity, receives distance and carries out electrospinning for 16cm, being collected into fibre diameter after 10h is
600nm~800nm, thickness are 100~150 μm of tunica fibrosa.The miRNA theory amount of containing is 50ng/mg in this sample
(miRNA/PELCL), actually the amount of containing reaches 30ng/mg (miRNA/PELCL), and envelop rate reaches 60%, prominent to release rate 20%
Below.
Claims (8)
1. one kind contain glucan-g- it is poly- (L- lysine)-VAPG/ nucleic acid complexes polylactide tunica fibrosa, it is characterized in that fine
Dimension film be by a diameter of 600~1200nm electrospinning fibre and a diameter of 50~100nm glucan-g- it is poly- (L- lysine)-
VAPG/ nucleic acid complexes nanoparticles are molecular, and the thickness of tunica fibrosa is 60~150 μm.
2. tunica fibrosa as claimed in claim 1, it is characterized in that the glucan-g- it is poly- (L- lysine)-VAPG, structural formula is such as
Under：
K=18~24, r=13~19, n=1~8, l=7~22.
3. tunica fibrosa as claimed in claim 1, it is characterized in that the core containing 50~200 nanograms in every milligram of electrospun fiber membrane
Acid.
4. tunica fibrosa as claimed in claim 1, it is characterized in that described nucleic acid is miRNA, described polylactide co polymer
Including polyethylene glycol-b- poly- (lactide-co-caprolactone) (PELCL) or poly- (lactide-co-glycolide) (PLGA), wherein third
The mol ratio of lactide and caprolactone is 3:1.
5. it is a kind of as claimed in claim 1 contain glucan-g- it is poly- (L- lysine)-VAPG/ nucleic acid complexes polylactide
The preparation method of tunica fibrosa, it is characterized in that comprising the following steps：
(1) PELCL or PLGA are dissolved in chloroform/N, N '-dimethyl formamide in the mixed solvent, add 10~12mg/mL's
F127 is configured to solution that concentration is 100~300mg/mL as oil phase as emulsifying agent；
(2) at room temperature, by glucan-g- it is poly- (L- lysine)-VAPG polymer and nucleic acid is dissolved in coke diethyl phthalate respectively
(DEPC) in water, and according to glucan-g- it is poly- (L- lysine)-VAPG polymer and miRNA mass ratioes be (2~4)：1 room temperature
Under compound 15~45min, add 52~292 μ L TE buffer solutions form homogeneous aqueous phase solution；
(3) according to the volume ratio 1 of aqueous phase/oil phase:10~1:25, aqueous phase solution is added in oil phase, vortex oscillation 0.5~2
Hour obtained dispersion liquid, using single syringe pump apparatus, electrospinning is carried out, obtain the glucan-g- that contains that thickness is 60~150 μm and gather
(L- lysine)-VAPG/ nucleic acid complexes polylactide co polymer tunica fibrosa.
6. preparation method as claimed in claim 5, it is characterised in that：PELCL weight average molecular weight is (5~10) × 104,
PLGA weight average molecular weight is (5~10) × 104, glucan-g- it is poly- (L- lysine)-VAPG weight average molecular weight for (1.5~
3.6)×104。
7. preparation method as claimed in claim 5, it is characterised in that：Using single syringe pump apparatus, using voltage as 10~16kV,
It is 12~16cm to receive distance, and it is that 0.3~0.6mL/h carries out electrospinning to disperse flow quantity.
8. preparation method as claimed in claim 2, it is characterised in that chloroform/DMF mixed solvent volume ratio
8:1~4:1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710554356.3A CN107551318B (en) | 2017-07-06 | 2017-07-06 | Polylactide fiber membrane for entrapping glucan-g-poly (L-lysine) -VAPG/nucleic acid complex and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710554356.3A CN107551318B (en) | 2017-07-06 | 2017-07-06 | Polylactide fiber membrane for entrapping glucan-g-poly (L-lysine) -VAPG/nucleic acid complex and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107551318A true CN107551318A (en) | 2018-01-09 |
| CN107551318B CN107551318B (en) | 2020-04-14 |
Family
ID=60973047
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710554356.3A Expired - Fee Related CN107551318B (en) | 2017-07-06 | 2017-07-06 | Polylactide fiber membrane for entrapping glucan-g-poly (L-lysine) -VAPG/nucleic acid complex and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107551318B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108619569A (en) * | 2018-04-11 | 2018-10-09 | 天津大学 | Three-layer artificial blood vessel electrospinning membrane loaded with micro nucleic acid and preparation method and application thereof |
| CN110975007A (en) * | 2019-12-09 | 2020-04-10 | 宁夏医科大学 | bFGF-loaded guided tissue regeneration membrane with core-shell structure and preparation method thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102321242A (en) * | 2011-08-22 | 2012-01-18 | 上海市肿瘤研究所 | Polyethylene glycol-polylactic acid-poly-L-lysine copolymer, preparation method thereof and application thereof as gene or drug vector |
| CN105039412A (en) * | 2014-02-14 | 2015-11-11 | 阿克伦大学 | Dextran-peptide hybrid for efficient gene delivery |
| CN106474488A (en) * | 2015-08-27 | 2017-03-08 | 天津大学 | A kind of superfine fibre film of load trimethyl chitosan chloride-polyethylene glycol-REDV/ nucleic acid and preparation method thereof |
| CN106581751A (en) * | 2016-12-31 | 2017-04-26 | 天津大学 | PELCL/polycaprolactone-g-polyethylene glycol-REDV electrospun fiber membrane and preparation method |
-
2017
- 2017-07-06 CN CN201710554356.3A patent/CN107551318B/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102321242A (en) * | 2011-08-22 | 2012-01-18 | 上海市肿瘤研究所 | Polyethylene glycol-polylactic acid-poly-L-lysine copolymer, preparation method thereof and application thereof as gene or drug vector |
| CN105039412A (en) * | 2014-02-14 | 2015-11-11 | 阿克伦大学 | Dextran-peptide hybrid for efficient gene delivery |
| CN106474488A (en) * | 2015-08-27 | 2017-03-08 | 天津大学 | A kind of superfine fibre film of load trimethyl chitosan chloride-polyethylene glycol-REDV/ nucleic acid and preparation method thereof |
| CN106581751A (en) * | 2016-12-31 | 2017-04-26 | 天津大学 | PELCL/polycaprolactone-g-polyethylene glycol-REDV electrospun fiber membrane and preparation method |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108619569A (en) * | 2018-04-11 | 2018-10-09 | 天津大学 | Three-layer artificial blood vessel electrospinning membrane loaded with micro nucleic acid and preparation method and application thereof |
| CN110975007A (en) * | 2019-12-09 | 2020-04-10 | 宁夏医科大学 | bFGF-loaded guided tissue regeneration membrane with core-shell structure and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107551318B (en) | 2020-04-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Huang et al. | Electrospun poly (butylene succinate)/cellulose nanocrystals bio-nanocomposite scaffolds for tissue engineering: Preparation, characterization and in vitro evaluation | |
| Kim et al. | Injectable in situ–forming pH/thermo-sensitive hydrogel for bone tissue engineering | |
| Lee et al. | Poly (L-lactic acid)/hydroxyapatite nanocylinders as nanofibrous structure for bone tissue engineering scaffolds | |
| Zhou et al. | Functional electrospun fibrous scaffolds with dextran-g-poly (l-lysine)-VAPG/microRNA-145 to specially modulate vascular SMCs | |
| Liu et al. | Controllable structure, properties, and degradation of the electrospun PLGA/PLA‐blended nanofibrous scaffolds | |
| Kim et al. | Temperature responsive chemical crosslinkable UV pretreated hydrogel for application to injectable tissue regeneration system via differentiations of encapsulated hMSCs | |
| Tsai et al. | Electrospun chitosan–gelatin–polyvinyl alcohol hybrid nanofibrous mats: Production and characterization | |
| Shafiq et al. | Stem cell recruitment, angiogenesis, and tissue regeneration in substance P‐conjugated poly (l‐lactide‐co‐ɛ‐caprolactone) nonwoven meshes | |
| Gang et al. | Highly porous three-dimensional poly (lactide-co-glycolide)(PLGA) microfibrous scaffold prepared by electrospinning method: A comparison study with other PLGA type scaffolds on its biological evaluation | |
| Xu et al. | Chemical crosslinking and biophysical properties of electrospun hyaluronic acid based ultra-thin fibrous membranes | |
| CN1733311A (en) | The preparation method of the nanofiber of a kind of packaging medicine or somatomedin | |
| CN101787120B (en) | Triblock polyamino acid and hydrogel thereof | |
| US20210008253A1 (en) | Elongate scaffold comprising inner and outer portion | |
| Mao et al. | Bio-orthogonal click reaction-enabled highly specific in situ cellularization of tissue engineering scaffolds | |
| CN102188755A (en) | Method for preparing protein-loaded tissue engineering fiber support | |
| CN1995099A (en) | Degradable chemically-crosslinked aquagel and its preparation method | |
| CN107551318A (en) | Contain the polylactide tunica fibrosa and preparation method of poly- (L lysines) the VAPG/ nucleic acid complexes of glucan g | |
| CN102397585A (en) | Fiber bracket containing growth factors and preparation method thereof | |
| CN106729976A (en) | A kind of PELCL/ polycaprolactones REDV electrospun fiber membranes and preparation method | |
| KR20120090746A (en) | Sol-gel transition chitosan-polymer composite and uses of the same | |
| CN101880381B (en) | Segmented copolymer modified by polyethylene glycol 1000 vitamin E succinic acid ester, preparation method and applications thereof | |
| Ghasemkhah et al. | Potential core–shell designed scaffolds with a gelatin‐based shell in achieving controllable release rates of proteins for tissue engineering approaches | |
| CN105315412A (en) | Technology for preparing high-molecular-weight MPLGA by directly grafting maleic anhydride onto PLGA | |
| CN102908668A (en) | Preparation method of induced growth type absorbable patch | |
| CN103469347A (en) | Preparation method of aliphatic polyester nanofiber with neutral pH after degradation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Address after: 300350 District, Jinnan District, Tianjin Haihe Education Park, 135 beautiful road, Beiyang campus of Tianjin University Applicant after: Tianjin University Address before: 300072 Tianjin City, Nankai District Wei Jin Road No. 92, Tianjin University Applicant before: Tianjin University |
|
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20200414 Termination date: 20200706 |